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The baseline model assumed that universal adolescent or adult vaccination would have no impact on infant disease. In an alternative analysis, the potential to reduce infant transmission for each strategy was varied, assuming the vaccine delivery rates used in the baseline analysis.
Methods used to derive estimates of effectiveness
Experts' opinion was relied on where estimates were unavailable or uncertain. A modified Delphi process was used to obtain the estimates.
Estimates of effectiveness and key assumptions
Different assumptions about reduced infant transmission were used in an alternative analysis to address the potential impact of herd immunity. Each vaccination strategy was estimated to reduce infant disease as follows: no vaccination, 0%; 1-time adolescent vaccination, 17%; 1-time adult vaccination, 10%; adult vaccination with 10-year boosters, 17%; and adolescent and adult vaccination with 10-year boosters, 35%.
For the postpartum vaccination strategy, infant disease was estimated to be reduced by 40% in both baseline and alternative analyses, on the basis of 66% vaccine delivery and 87% vaccine efficacy and the assumption that caregivers were responsible for 70% of infant disease.
Measure of benefits used in the economic analysis
The measures of benefit were the pertussis cases prevented and the quality-adjusted life-years (QALYs). Preferences for study-specific health states were obtained from adults and parents of adolescents with confirmed pertussis disease in a separate study (Lee et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic detail). The time trade-off method was used to measure preference for health states.
Direct costs
The direct costs were disease costs and vaccine costs. The former (disease costs) included medical costs for cough and pneumonia for adolescents and adults, medical cost for respiratory disease, respiratory disease with hospitalisation, neurologic disease and death for infants. The latter (vaccine costs) included vaccine price, cost of vaccine administration, cost of vaccine visit, cost of local reaction, cost of systemic reaction and cost of anaphylaxis. The disease costs for adolescents and adults were based on a published study (Lee et al. 2004 , see 'Other Publications of Related Interest' below for bibliographic detail). The medical costs for infants were estimated from health service utilisation data from the Massachusetts enhanced pertussis surveillance system multiplied by the unit cost per service, and from sources such as the Medicare fee schedule and the American Academy of Paediatrics fee schedule. The estimations of vaccine price and quantities were assumptions. The costs were adjusted for inflation to 2004 US dollars. Future costs were discounted at an annual rate of 3%, which was relevant as the time horizon was lifetime.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs included non-medical costs attributable to pertussis. The non-medical costs for adolescents and adults were based on a published study (Lee et al. 2004 ). The non-medical costs for infants were estimated to include the time costs of work missed for one adult while the child received medical care (2 hours per office visit and 8 hours per day for hospitalisations). The median wage rate for female workers aged 25 to 35 years was used to calculate the time costs related to infant disease. The costs were adjusted for inflation to 2004 US dollars.
Currency

US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were carried out to evaluate the different assumptions about reduced infant transmission and other baseline assumptions. Two-way sensitivity analyses of significant parameters identified in the one-way analyses were also examined. 1-time adolescent vaccination would potentially cause 60,800 local adverse events and 30,400 systemic adverse events; 1-time adult vaccination would potentially cause 28,700 local adverse events and 14,300 systemic adverse events; adult vaccination with boosters would potentially cause 107,800 local adverse events and 53,900 systemic adverse events; adolescent and adult vaccination with boosters would potentially cause 168,600 local adverse events and 84,300 systemic adverse events; and postpartum vaccination would potentially cause 57,000 local adverse events and 28,500 systemic adverse events.
Estimated benefits used in the economic analysis
Cost results
With no vaccination programme, the overall costs for the cohort were $23.7 million from the health care payer perspective and $37.6 million from the societal perspectives. The adolescent and adult vaccination with boosters strategy had the highest total costs at $101.1 million (health care payer perspective) and $109.3 million (societal perspective), whereas the 1-time adolescent vaccination strategy cost $61.5 million (health care payer) and $70.6 million (societal).
Compared with no vaccination, the net costs for the cohort from the health care payer perspective were:
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Synthesis of costs and benefits
The estimated benefits and costs were combined by calculating the cost per case prevented and cost per QALY saved.
Compared with no vaccination, the 1-time adolescent vaccination strategy cost $1,200 per case prevented (health care payer perspective) and $1,100 per case prevented (societal perspective). The adolescent and adult vaccination with boosters strategy cost $9,400 per case prevented (health care payer) and $9,200 per case prevented (societal), compared with the next-best strategy of 1-time adolescent vaccination. All other strategies were dominated (i.e. they were more costly and less effective than alternative strategies).
When the incremental cost per QALY saved was examined, the baseline analysis demonstrated cost-effectiveness ratios of $23,000 per QALY saved (health care payer perspective) and $20,000 per QALY saved (societal perspective) for the 1-time adolescent vaccination strategy compared with no vaccination. All other strategies were dominated.
In sensitivity analyses, when the probability and cost estimates in the model were varied over plausible ranges, 1-time adolescent vaccination usually remained the most effective and cost-effective strategy, with a criterion of less than $50,000 per QALY saved. The adolescent and adult vaccination with boosters strategy became potentially costeffective from the societal perspective only if two conditions were met simultaneously. More specifically, if the disease incidence for adolescent and adults was at least 6 times higher than the base-case assumptions and the cost of vaccination was less than $10. Adult vaccination strategies were more costly and less effective than adolescent vaccination strategies. The results were sensitive to assumptions about disease incidence, vaccine efficacy, frequency of vaccine adverse events, and vaccine costs.
